| Combining single-cell genomics and machine learning to understand adaptive immune responses in early cancer. |
Dr Jamie Blundell |
Dept of Oncology |
| Development of novel cellular immunotherapies. |
Dr Mike Chapman |
MRC Toxicology Unit |
| Dissecting glioblastoma infiltration using integrated single cell and spatial genomics. |
Dr Omer Bayraktar |
Wellcome Sanger Institute |
| Drugging the undruggable: Therapeutically targeting key drivers of pro- and anti-oncogenic signalling in brain cancer and leukaemia. |
Dr Pau Creixell |
CRUK Cambridge Institute |
| Evaluation of dynamic metabolism in renal cancer patients treated with systemic therapy using intraoperative labelled nutrient delivery. |
Prof Grant Stewart |
Dept of Surgery |
| Exploring DNA damage and androgen inhibition (API) in early prostate cancer (PC): validation of biomarkers and mechanistic characterisation. |
Mr Harveer Dev |
Dept of Oncology |
| Exploring the biomarker potential and functional role of dysregulated microRNA expression in Wilms tumours. |
Prof Matthew Murray |
Dept. of Pathology |
| Generation and evaluation of non-activated CAR T cells for treatment of cancer. |
Dr Nicholas Matheson |
Dept of Medicine |
| Investigating mechanisms of drug resistance in paediatric cancers |
Prof Suzanne Turner |
Dept of Pathology |
| Rejuvenating the aged immune system by cell reprogramming during lung carcinogenesis. |
Dr Daniel Munoz-Espin |
Dept of Oncology |
| Spatially-resolved multi-omics to decipher the mediators of therapy resistance and disease progression in oesophageal adenocarcinoma. |
Prof Rebecca Fitzgerald |
Dept of Oncology |
| Towards a strategy for the early detection of lung cancer in never-smokers (LCINS). |
Dr Frank McCaughan |
Dept of Medicine |
| Understanding the evolutionary dynamics of myelodysplastic syndrome and factors that drive or impede progression to acute myeloid leukaemia. |
Dr Caroline Watson |
Dept of Oncology |
| Using UK population-wide data to develop individualised prognostic models in patients with early-stage melanoma. |
Mr Amit Roshan |
CRUK Cambridge Institute |
| Gene Therapy of Human Glioblastoma Tumour-Associated Macrophages. |
Dr Harry Bulstrode |
Cambridge Stem Cell Institute |
